On Feb. 24, 2020, Clover Biopharmaceuticals announced a research collaboration with GSK for its protein-based coronavirus vaccine candidate (COVID-19 S-Trimer).

GSK provided Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies. Having one of the largest in-house, commercial-scale cGMP biomanufacturing capabilities in China, Clover could potentially rapidly scale-up and produce large-quantities of a new coronavirus vaccine.